Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun 20;389(1-2):108-21.
doi: 10.1016/j.virol.2009.04.001. Epub 2009 May 2.

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo

Kaustuv Banerjee  1 , Sofija Andjelic, Per Johan Klasse, Yun Kang, Rogier W Sanders, Elizabeth Michael, Robert J Durso, Thomas J Ketas, William C Olson, John P Moore
Affiliations

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo

Kaustuv Banerjee et al. Virology. .

Abstract

The Env glycoproteins gp120 and gp41 are used in humoral immunity-based vaccines against human immunodeficiency virus (HIV-1) infection. One among many obstacles to such a vaccine is the structural defenses of Env glycoproteins that limit their immunogenicity. For example, gp120 mannose residues can induce immunosuppressive responses in vitro, including IL-10 expression, via mannose C-type lectin receptors on antigen-presenting cells. Here, we have investigated whether mannose removal alters gp120 immunogenicity in mice. Administering demannosylated gp120 (D-gp120) in the T(H)2-skewing adjuvant Alum induced approximately 50-fold higher titers of anti-gp120 IgG, compared to unmodified gp120. While the IgG subclass profile was predominantly T(H)2-associated IgG1, Abs of the T(H)1-associated IgG2a and IgG3 subclasses were also detectable in D-gp120 recipients. Immunizing with D-gp120 also improved T-cell responses. Giving an IL-10 receptor blocking MAb together with unmodified gp120 in Alum increased the anti-gp120 IgG titer, implicating IL-10 as a possible mediator of auto-suppressive responses to gp120.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Biochemical properties of demannosylated gp120
Preparations of gp120 were assessed for (A) m.wt. changes, (B) the presence of α(1–2,3,6)-mannosidase using a non-reducing 4–12% Bis-Tris NuPage gel. The D-gp120 preparation shown in (A) is from batch #2 after CHT column purification.
Figure 2
Figure 2. Antigenic properties of demannosylated gp120
Unmodified gp120, mannosidase-treated gp120 (D-gp120, batch #1) or gp120 processed in the absence of mannosidase (M-gp120) were captured onto ELIS plates via Ab D7324, then reacted with serial 3-fold dilutions of the antibodies indicated on each panel. The OD490 values displayed are the means from duplicate wells. The test MAbs recognize terminal mannoses (2G12); a discontinuous C1–C4 epitope (A32); a CD4-induced (CD4i) epitope (17b ± sCD4); V3 epitopes (447-52D, F425-B4e8); or epitopes overlapping the CD4 binding site (CD4BS) (b6, b12, 15e). CD4IgG2 binds the CD4Bs and HIVIG is a polyclonal antibody preparation derived from the sera of HIV-1-infected people.
Figure 3
Figure 3. Comparative immunogenicity of D-gp120 in BALB/c mice
Mice (5 per group) were immunized with gp120, M-gp120 or D-gp120 (batch #1) in Alum (A) or Quil A (B) adjuvants, as indicated. Anti-gp120 IgG titers were determined using a gp120 capture ELISA. Each symbol represents the mean (± SEM) reciprocal endpoint anti-gp120 titer for each group of mice (n=5). Titers <100 (grey shaded area) are considered negative. The mean reciprocal end-point titer values for prebleed samples were all < 1.0 × 102 (data not shown).
Figure 4
Figure 4. Comparative immunogenicity of D-gp120 in C57BL/6 mice
Mice were immunized with M-gp120 (grey symbols) or D-gp120 batch #1 (black symbols) at the times indicated by the arrows. Main figure: Alum adjuvant; inset, Quil A adjuvant. Each symbol represents the mean (± SEM) reciprocal endpoint anti-gp120 titer for each group of mice (n=5 initially, but n=4 for M-gp120/Alum from week 7 due to the death of one mouse from an unrelated cause). Titers <100 (grey shaded area) are considered negative.
Figure 5
Figure 5. The increased immunogenicity of D-gp120 is not due to contaminant mannosidase
Mice (C57BL/6, 5 per group) were immunized with M-gp120 (grey symbols) or D-gp120 (batch #2; enyzme free; black symbols) using alum adjuvant, at the times indicated by the arrows. Each symbol represents the mean (± SEM) reciprocal endpoint anti-gp120 titer for each group of mice. Titers <100 (grey shaded area) are considered negative.
Figure 6
Figure 6. Blocking IL-10 activity during immunization with gp120 in Alum adjuvant, but not Quil A, increases the anti-gp120 titer in C57BL/6 mice
Mice were immunized with gp120 in the presence of an anti-mIL-10R MAb (black symbols) or an isotype control MAb (white symbols) at the times indicated by the arrows (black, gp120; grey, MAbs). Main figure: Alum adjuvant; inset, Quil A adjuvant. Each symbol represents the mean (± SEM) reciprocal endpoint anti-gp120 titer for each group of mice (n=5 initially, but n=4 for gp120 + control MAb in Alum from week 2 due to the death of one mouse from an unrelated cause). Titers <100 (grey shaded area) are considered negative.
Figure 7
Figure 7. gp120-specific IgG subclass responses in C57BL/6 mice immunized with M-gp120 or D-gp120
Serum IgG subclasses were determined 7 weeks after primary immunization. Shown are reciprocal endpoint titers for each individual mouse (horizontal bar indicates median values) that received M-gp120 (grey symbols) or D-gp120 batch #1 (black symbols) in either Alum (panel A) or Quil A (panel B) adjuvants. Negative responders (titer < 100) are shown in the grey boxed area.
Figure 8
Figure 8. gp120-specific IgG subclass responses in C57BL/6 mice immunized with gp120 in the presence or absence of an IL-10 receptor Mab
Serum IgG subclasses were determined 7 weeks after primary immunization. Shown are reciprocal endpoint titers for each individual mouse (horizontal bar indicates median values) that received gp120 together with an anti-IL-10 receptor MAb (grey symbols) or an isotype control MAb (black symbols) in Alum adjuvant. Negative responders (titer < 100) are shown in the grey boxed area.
Figure 9
Figure 9. D-gp120 immunization improves antigen specific T cell responses
Unfractionated splenocytes (2.5 × 105 cells/well) derived from the indicated groups of C57BL/6 mice were cultured for 72h with 10μg/ml of recombinant gp120 (left panel), 2μg/ml of anti-CD3 (center panel) or media (right panel). Cytokine levels in supernatants from triplicate wells were measured by ELISA and are expressed in pg/ml as the mean value ± SD above the respective assay detection limits. The mice were immunized with M-gp120 (white bars) or D-gp120 batch #1 (black bars) in the adjuvant indicated at the foot of the figure. * p < 0.05 (one-tailed Student’s t test).
Figure 10
Figure 10. Antigen-specific T cell responses from gp120-immunized C57BL/6 mice
Unfractionated splenocytes (2.5 × 105 cells/well) derived from the indicated groups of C57BL/6 mice were cultured for 72h with 10μg/ml of recombinant gp120 (left panel), 2μg/ml of anti-CD3 (center panel) or media (right panel). Cytokine levels in supernatants from triplicate wells were measured by ELISA and are expressed in pg/ml as the mean value ± SD (the y-axis starts at the manufacturer specified detection limit for each cytokine). The mice were immunized with gp120 in the adjuvant indicated at the foot of the figure, and in the presence of an isotype control MAb (white bars) or the anti-mIL-10R MAb (black bars). * p < 0.05 (one-tailed Student’s t test).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752–62. - PubMed
    1. Allaway GP, Ryder AM, Beaudry GA, Maddon PJ. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res Hum Retroviruses. 1993;9(7):581–7. - PubMed
    1. Barcova M, Kacani L, Speth C, Dierich MP. gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-gamma production. J Infect Dis. 1998;177(4):905–13. - PubMed
    1. Beddows S, Schulke N, Kirschner M, Barnes K, Franti M, Michael E, Ketas T, Sanders RW, Maddon PJ, Olson WC, Moore JP. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol. 2005;79(14):8812–27. - PMC - PubMed
    1. Bergman MP, Engering A, Smits HH, van Vliet SJ, van Bodegraven AA, Wirth HP, Kapsenberg ML, Vandenbroucke-Grauls CM, van Kooyk Y, Appelmelk BJ. Helicobacter pylori modulates the T helper cell 1/T helper cell 2 balance through phase-variable interaction between lipopolysaccharide and DC-SIGN. J Exp Med. 2004;200(8):979–90. - PMC - PubMed

Publication types

MeSH terms